“The INFORM HER2 Dual ISH assay improves treatment of breast cancer patients by providing clinicians increased accuracy and faster time to result compared to fluorescent in situ hybridization (FISH) assays,” said Greg Yap, Lifecycle Leader, Advanced Staining Assays at Ventana. “In a Ventana clinical study comparing HER2 Dual ISH to FISH, our findings showed that more patients would have received the correct result and be identified as potential candidates for Herceptin therapy using our ISH test. In addition, FISH assays for gene amplification must be run manually by skilled technologists, making them labor-intensive and time consuming. The average turn-around time for HER2 FISH testing in breast tissue is 2-3 days as opposed to approximately 13 hours for HER2 Dual ISH testing. We are pleased to offer all of our customers and patients worldwide our HER2 Dual ISH assay with its benefits over traditional FISH testing.”
The HER2 Dual ISH assay combined with the PATHWAY HER2 (4B5) immunohistochemistry assay provides clinicians with highly accurate tools for determining the HER2 status of a patient. This enables clinician and patient to move forward with a targeted treatment plan.